DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The FDA approved Wegovy HD (semaglutide 7.2mg), the first weight management injection shown superior to its predecessor, with patients achieving 20.7% mean weight loss versus 17.5% at the existing 2.4mg dose. Available April 2026 at retail pharmacies and telehealth platforms, it is indicated for patients who have tolerated 2.4mg for at least 4 weeks and need additional weight reduction.
Professional Impact
- 31.2% of Wegovy HD patients achieved at least 25% body weight loss versus 16.7% on standard Wegovy, a clinically meaningful difference for patients with obesity-related comorbidities
- Dysesthesia and altered skin sensation occurred more frequently at 7.2mg, a new adverse effect profile requiring patient counseling before prescribing
- Approval was based on a non-diabetic population only; efficacy and safety data in patients with diabetes or PCOS remain unestablished at this dose
- Telehealth availability expands patient access but increases likelihood patients will self-escalate outside appropriate clinical supervision
Action Items
- Confirm patients have tolerated 2.4mg for at least 4 weeks before considering escalation to Wegovy HD
- Counsel patients on the increased risk of skin sensation changes, including hyperesthesia and paresthesia, at the higher dose
- Screen for weight-related comorbidities to establish medical indication before prescribing
- Monitor telehealth-prescribed patients for unsupervised dose escalation and adverse effects at follow-up visits
More Device/Drug Approvals
